GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (OTCBB: SENH), a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease, today announced the pricing of an underwritten public offering of 15,800,000 shares of its common stock at a public offering price of $2.85 per share. All of the shares in the offering are to be sold by Senseonics Holdings, Inc. The offering is expected to close on or about March 23, 2016, subject to the satisfaction of customary closing conditions. Senseonics Holdings, Inc. has granted the underwriters a 30-day option to purchase up to 2,370,000 additional shares of common stock.
Leerink Partners LLC and Canaccord Genuity Inc. are acting as joint book-running managers for the offering. Raymond James & Associates, Inc. is acting as lead manager with BTIG, LLC as co-manager for the offering.
In connection with the offering, the common stock of Senseonics Holdings, Inc. has been approved for listing on the NYSE MKT. Trading is scheduled to commence on the NYSE MKT on Friday, March 18, 2016 under the symbol "SENS."
A registration statement on Form S-1 relating to the public offering of the shares of common stock described above was filed with, and declared effective by, the Securities and Exchange Commission (“SEC”). A preliminary prospectus related to the offering was filed with the SEC on March 8, 2016, and a final prospectus related to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the final prospectus related to the offering may also be obtained from Leerink Partners LLC, 299 Park Avenue, 21st Floor, New York, NY 10171, Attn: Prospectus Department, by calling (212) 277-6000, or Canaccord Genuity, Inc., 99 High Street, Boston, MA 02110, Attn: Prospectus Department, by calling (617) 371-3900. An electronic copy of the preliminary prospectus relating to the offering is also available on the website of the SEC at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Our first generation continuous glucose monitoring (CGM) system, Eversense, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.